111
TITLE: The trade of live crustaceans in Portugal: space for technological improvements  Full Text
AUTHORS: Sara Barrento ; Antonio Marques; Sonia Pedro ; Paulo Vaz Pires ; Maria Leonor Nunes ;
PUBLISHED: 2008, SOURCE: ICES JOURNAL OF MARINE SCIENCE, VOLUME: 65, ISSUE: 4
INDEXED IN: Scopus WOS CrossRef
112
TITLE: Fulvestrant in metastatic breast cancer previously treated with aromatase inhibitors  Full Text
AUTHORS: Ribeiro, J; Luis, I; Fortunato, M; Correia, L; Quintela, A; Cortes, P; Costa, L;
PUBLISHED: 2008, SOURCE: 6th European Breast Cancer Conference in EJC SUPPLEMENTS, VOLUME: 6, ISSUE: 7
INDEXED IN: WOS CrossRef
113
TITLE: Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
AUTHORS: Aapro, M; Abrahamsson, PA; Body, JJ; Coleman, RE; Colomer, R; Costa, L; Crino, L; Dirix, L; Gnant, M; Gralow, J; Hadji, P; Hortobagyi, GN; Jonat, W; Lipton, A; Monnier, A; Paterson, AHG; Rizzoli, R; Saad, F; Thuerlimann, B;
PUBLISHED: 2008, SOURCE: ANNALS OF ONCOLOGY, VOLUME: 19, ISSUE: 3
INDEXED IN: Scopus WOS CrossRef
114
TITLE: Markers of bone turnover (ICTP, NTX) and serum matrix metalloproteinase 1 (MMP1) as prognostic markers in breast cancer patients with bone metastases (BM) treated with bisphosphonates (BP)
AUTHORS: Costa, L; Alho, I; Casimiro, S; Oliveira, AG; Bicho, M; Carvalho, R; Fernandes, A; Ali, S; Leitzel, K; Demers, L; Lipton, A;
PUBLISHED: 2008, SOURCE: CLINICAL & EXPERIMENTAL METASTASIS, VOLUME: 25
INDEXED IN: WOS
115
TITLE: Elevated plasma cytokine levels in patients with bone metastasis
AUTHORS: Leitzel, K; Demers, L; Suhail, M; Anderson, M; Kelly, P; Costa, L; Lipton, A;
PUBLISHED: 2008, SOURCE: CLINICAL & EXPERIMENTAL METASTASIS, VOLUME: 25
INDEXED IN: WOS
116
TITLE: Bisphosphonates: Reducing the risk of skeletal complications from bone metastasis  Full Text
AUTHORS: Costa, L;
PUBLISHED: 2007, SOURCE: BREAST, VOLUME: 16, ISSUE: SUPPL. 3
INDEXED IN: Scopus WOS CrossRef
117
TITLE: Serum carboxyterminal telopeptide (ICTP) as a prognostic marker in bone metastases (BM) treated with bisphosphonates.
AUTHORS: Costa, L; Carvalho, R; Oliveira, AG; Bicho, M; Fernandes, A; Rodrigues, T; Ali, S; Leitzel, K; Demers, L; Lipton, A;
PUBLISHED: 2006, SOURCE: 42nd Annual Meeting of the American-Society-of-Clinical-Oncology in JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 24, ISSUE: 18
INDEXED IN: WOS
118
TITLE: Gnotobiotically grown aquatic animals: opportunities to investigate host-microbe interactions  Full Text
AUTHORS: Marques, A; Ollevier, F; Verstraete, W; Sorgeloos, P; Bossier, P;
PUBLISHED: 2006, SOURCE: JOURNAL OF APPLIED MICROBIOLOGY, VOLUME: 100, ISSUE: 5
INDEXED IN: Scopus WOS CrossRef
119
TITLE: Breast cancer patients without pain are at risk for skeletal-related events (SRES) and may have better outcomes with zoledronic acid compared with pamidronate
AUTHORS: Luis Costa; Yin Miao Chen; Nana Shirina;
PUBLISHED: 2006, SOURCE: 30th Congress of the European-Society-for-Medical-Oncology in ANNALS OF ONCOLOGY, VOLUME: 17
INDEXED IN: WOS
120
TITLE: Breast cancer patients without pain are at risk for skeletal-related events and may have better outcomes with zoledronic acid compared with pamidronate.
AUTHORS: Costa, L; Chen, YM;
PUBLISHED: 2006, SOURCE: 29th Annual San Antonio Breast Cancer Symposium in BREAST CANCER RESEARCH AND TREATMENT, VOLUME: 100
INDEXED IN: WOS
Page 12 of 14. Total results: 131.